CanSinoBIO using same technique as Johnson & Johnson reports no case of blood clot

Chinese vaccine producer CanSinoBIO said on Wednesday that it had not received any report of blood clots after vaccination of millions of people with its recombinant adenovirus vector COVID-19 vaccine, Global Times reported.

However, amid reports that inoculation has been halted in various countries for AstraZeneca and Johnson & Johnson’s COVID-19 vaccines, which use the same technical method as CanSinoBIO.

Although CanSinoBio’s vaccine uses the same technique, it uses different adenovirus than the other two companies. CanSinoBio uses adenovirus type-5 as vector, a common adenovirus among humans, while AstraZeneca uses chimpanzee adenovirus and Johnson & Johnson uses adenovirus type-26.